Oral supplementation with Nicotinamide Riboside treatment protects RGCs in DBA/2J mouse model
Nan Zhang, Ying Li, Xian Zhang, Micah A. Chrenek, Jiaxing Wang, Preston E. Girardot, Jana T Sellers, Charles Brenner, Xiangqin Cui, Eldon E. Geisert, John M. Nickerson, Jeffrey H. Boatright
This study shows that oral Nicotinamide Riboside (NR) treatment protects retinal ganglion cells (RGCs) and optic nerve axons in DBA/2J mice, likely through increased retinal NAD+ levels, and also prevents iris depigmentation and delayed IOP elevation.
bioRxiv · Dec 3, 2024 · PreprintNeuroscience